Open Internet by MindsNet

Overcoming the 'undruggable' KRAS target in pancreatic cancer

KRAS has been a challenging target for drug development due to its minimal binding sites, making it difficult to create effective treatments. Pancreatic cancer has been particularly resistant to oncology drug development, with limited treatment options and poor patient outcomes. The 'undruggable' nature of KRAS has led to decades of failed hypotheses and abandoned research efforts.

Science, Medicine, Oncology